Mariam is evaluating the efficacy of combinatorial therapies that include chemotherapeutic drugs and gut microbiota to overcome resistance to immune checkpoint blockade. She is also interested in understanding how tumors evolve under immune pressure to identify tumor-specific neoantigens that could be selectively targeted in the clinic.